Inspirna

Inspirna is a biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need.

[Inspirna @inspirna]

Hear from Abdul Rafeh Naqash, MD who recently sat down with @OncLive to discuss Inspirna’s clinical data presented at #SITC2024 of abequolixron, a novel LXR agonist that activates APOE, for patients with #NSCLC: https://t.co/ZeWlBo53Bt

[OncLive.com @OncLive]

Abequolixron plus docetaxel generated preliminary efficacy signals in the second- and third-line settings in recurrent advanced nonsquamous NSCLC. #lcsm #oncology https://t.co/OWfmumge9Z

[Inspirna @inspirna]

Inspirna is at #SITC2024, where we’re presenting on Abequolixron, our first-in-class oral immunotherapy, in combination with docetaxel for the treatment of patients with advanced non-small cell lung cancer. Full poster here: https://t.co/f4PPGju7nS #NSCLC

[Inspirna @inspirna]

Welcome Karim Benhadji, M.D., as Inspirna’s new Chief Medical Officer! With 20 years of experience in late stage oncology drug development, his leadership will be crucial as we implement our future clinical plan for Inspirna. Read here: https://t.co/Y2jencVJOG

[Inspirna @inspirna]

Welcome Darren Wong, Ph.D., as Inspirna’s new SVP of Translational Medicine. Dr. Wong brings over 20 years of experience in drug discovery and development and is an important addition to our team as we continue to develop our pipeline of #cancer drug candidates.

[Inspirna @inspirna]

It’s #colorectalcancerawarenessmonth. We’re underscoring the importance of new treatment options for #CRC patients, which is why we’re evaluating ompenaclid (RGX-202) to provide long-term survival benefits without decreasing quality of life. Learn more: https://t.co/xxrfZWr10C

[Inspirna @inspirna]

Inspirna is dedicated to stopping cancer progression and providing long-term survival benefits for patients. Through our miRNA-DRIVEr platform, we aim to reveal & pursue new targets which address a large unmet needs. Learn about us: https://t.co/dEYXsCNQNU #WorldCancerDay

[Inspirna @inspirna]

Looking forward to #JPM24, where Inspirna CEO, Usman “Oz” Azam, M.D. will present on our proprietary discovery platform, miRNA-DRIVEr, which reveals new cancer drivers through microRNA profiling. More details: https://t.co/cKEkX0y44y

[Inspirna @inspirna]

Today, we announced our licensing agreement with Merck KGaA, Darmstadt, Germany, @EMDSerono, for ompenaclid (RGX-202), for the treatment of #colorectalcancer and SLC6a8 targeting follow-on compounds. Full press release: https://t.co/36sBCbdPhq

[Inspirna @inspirna]

Tomorrow at the @Stifel Healthcare Conference: CFO/COO & co-founder David Darst will present the latest clinical data from our pan-RAS program ompenaclid for #colorectalcancer and discuss Inspirna's target discovery platform, miRNA-DRIVEr. Tune in: https://t.co/bclSopqZtU

[Inspirna @inspirna]

Thank you to #ESMO23 for hosting a great conference, and to everyone who had the opportunity to visit our poster, now available on our website. A replay of our virtual KOL panel discussing the data is available here: https://t.co/FyaJK2CQKP

[Inspirna @inspirna]

We’re excited to share encouraging efficacy and safety data from the Phase 1b/2 study of Ompenaclid (RGX-202) in advanced #colorectalcancer presented at #ESMO23. Full press release here: https://t.co/cPsEAq9rD7

[Inspirna @inspirna]

Inspirna is presenting clinical data from the Phase 1b/2 study of Ompenaclid (RGX-202) in advanced #colorectalcancer at #ESMO23. Join our virtual KOL panel on Sunday, October 22, at 6:30 PM CEST/12:30 PM ET to discuss the data. More details: https://t.co/IIAAJtlYto

[Inspirna @inspirna]

We’ve launched our new website! Discover how we're working to target previously untreatable cancers and converting them into manageable, chronic conditions: https://t.co/ZOiMHXdaUs

[Inspirna @inspirna]

Thank you to all those who joined us on Friday at our reception during #ASCO23. We’re excited about the progress of our pipeline of novel #cancer drug candidates and look forward to providing updates in the future. Learn more about us: https://t.co/c6Wn7Ny1S0

[Inspirna @inspirna]

This Thursday, Inspirna CEO, Usman “Oz” Azam, will present a company overview and discuss advances in our #oncology pipeline at the @Jefferies Healthcare Conference. More details: https://t.co/UmDRF3i4N7

[Inspirna @inspirna]

Welcome Dr. Usman “Oz” Azam as Inspirna’s new CEO! Oz brings decades of drug development experience & will be integral in leading the company & advancing our pipeline. We also thank Masoud Tavazoie for his successful years of leading Inspirna. Learn more: https://t.co/wjuQyL44ri

[Inspirna @inspirna]

Did you know that #colorectalcancer is the third most common cancer diagnosed in the U.S.? That’s why we’re developing a new potential therapy, ompenaclid (RGX-202), currently in a Phase 1b/2 clinical trial. Learn more: https://t.co/4bxOc6YmPq #ColorectalCancerAwarenessMonth

[Inspirna @inspirna]

This month, Inspirna is participating in 1x1s at the Cowen & Co. Annual Health Care Conference and Barclays Global Healthcare Conference. Learn more about us and our mission to develop novel #cancer medicines: https://t.co/DEqsCwnPg3

[Inspirna @inspirna]

On #WorldCancerDay, we stand in support of everyone dedicated to helping patients in need. At Inspirna, we’re developing a drug candidate called ompenaclid to treat #colorectalcancer. Watch our educational video here to learn more about how it works: https://t.co/reN1Ek4e9j

[Inspirna @inspirna]

Our team is attending the private track at the SVB Securities Global Biopharma Conference next week. We look forward to connecting with investors and continue to share our story and mission to develop novel #cancer medicines. Learn more about us: https://t.co/YoffZxuX5g